<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154857">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02098291</url>
  </required_header>
  <id_info>
    <org_study_id>PC1</org_study_id>
    <nct_id>NCT02098291</nct_id>
  </id_info>
  <brief_title>An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma</brief_title>
  <acronym>PC1</acronym>
  <official_title>Phase II, Open, Single-center Study to Determine the Antibody Response to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Advances Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Advances Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine the effect of jaundice on the ability of G17DT to
      generate antibodies before and after treatment of biliary obstruction due to advanced
      pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">February 2002</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacodynamic</measure>
    <time_frame>Up to week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-Gastrin 17 antibodies were determined at baseline (week0) and measured at subsequent visits during the first 16 weeks after the first G17DT injection to determine the effect of jaundice on the ability of patients to generate antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>Up to week 139</time_frame>
    <safety_issue>No</safety_issue>
    <description>The vital status was monitored throughout the study and was followed up to the death of the last patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Up to week 60</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, defined as any event involving adverse reactions, illnesses with onset during the study, or exacerbations of pre-exisiting illnesses, were assessed at each visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>G17DT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G17DT</intervention_name>
    <arm_group_label>G17DT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histological or cytological confirmation of pancreatic carcinoma who
             were not suitable for pancreatic tumour resection with curative intent

          -  Patients who had not received chemotherapy in the previous month and who would either
             not receive chemotherapy in the period of study or who would commence gemcitabine
             treatment in week 4 of the study

          -  Male or female patients over 18 years of age

          -  Patients with a life expectancy of at least 2 months

          -  Patients must have given written informed consent

          -  Patients with a Karnofsky Performance Status score of â‰¥ 50%

          -  Patients who would not receive chemotherapy in the period of the Extension Survival
             Study, except for concomitant gemcitabine ongoing at visit (for extension study)

        Exclusion Criteria:

          -  History of other malignant disease except non-melanomatous skin carcinoma or in situ
             carcinoma of the uterine cervix

          -  Concomitant use or anticipated use in the period of the study of radiotherapy

          -  Chemotherapy in the previous month preceding screening, anticipated concomitant use
             of chemotherapy between screening and week 4 of the study or anticipated useof
             chemotherapeutic agents other than gemcitabine from week 4 for the period of the
             study

          -  Use in the past month or concomitant use of immunosuppressants, including systemic
             (i.e. oral or injected) corticosteroids

          -  Females who were pregnant, planning to become pregnant or lactating

          -  Patients taking part in another study involving an investigational or licensed drug
             or device in the three months preceding enrolment or during the study

          -  Haematological indicators:

        Haemoglobin &lt;9.5g/dl White blood cell count &lt;3.5 x 109/l Platelets &lt;100 x 109/l
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
